Friday, July 10, 2026
🇺🇸 FDA

pharma · Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) · Advanced Solid Tumor

Daiichi Sankyo US

Daiichi Sankyo

Daiichi Sankyo US trial registry — 58 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US HQ
4,386 Employees
NMPA registrant Type
Company details
Status
Public
HQ
211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US
Employees
4,386
Programs
58
Drugs
66
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Trials

Daiichi Sankyo US clinical trials

Registry index of 58 ClinicalTrials.gov studies linked to Daiichi Sankyo US programs — each row shows trial ID, program name, phase, status, and indication.

Daiichi Sankyo US trial registry — 58 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Daiichi Sankyo US.

  1. DSE-BMP-0004-CIS-MA — Phase 1

    Clinical update

  2. DS8201-A-U302 — Phase 3

    Clinical update

  3. DS8201-772 — Phase 3

    Clinical update

  4. DS6000-109 — Phase 3

    Clinical update

  5. DS1062-A-U304 — Phase 3

    Clinical update

  6. U31402-A-U301 — Phase 3

    Clinical update

  7. DSE-BMP-0003-CIS-MA — Phase 1

    Clinical update

  8. DSE-BMP-0002-CIS-MA — Phase 1

    Clinical update

Trial registry

58 studies
  2. 2023-506330-73-00

    DS-8201a

    Phase 3 active small_molecule

    Advanced (unresectable or metastatic) human epidermal growth receptor 2 (HER2)-expressing/HER2-mutated solid tumors

    CTIS ↗
  5. 2023-507914-28-00

    DS6000-109

    Phase 3 active small_molecule

    Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer

    CTIS ↗
  16. 2023-509632-26-00

    Ifinatamab deruxtecan

    Phase 2 active small_molecule

    Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma)

    CTIS ↗
  27. 2024-513307-13-00

    Raludotatug Deruxtecan

    Phase 2 active small_molecule

    Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC)

    CTIS ↗
  31. 2024-516916-93-00

    DS3201-324

    Phase 1 active small_molecule

    This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.